New Zealand markets close in 5 hours 53 minutes
  • NZX 50

    11,828.11
    -24.82 (-0.21%)
     
  • NZD/USD

    0.6282
    -0.0001 (-0.02%)
     
  • ALL ORDS

    7,381.10
    +19.20 (+0.26%)
     
  • OIL

    87.65
    -0.46 (-0.52%)
     
  • GOLD

    1,777.00
    +0.30 (+0.02%)
     

This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

·4-min read
This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting